Difructose anhydride III and sodium caprate activate paracellular transport via different intracellular events in Caco-2 cells.
A nondigestible disaccharide, difructose anhydride (DFA) III, is known to activate calcium transport via tight junctions (TJs); however, the characteristics of and mechanisms for the increase in paracellular transport induced by DFAIII have not been clarified. We compared the effect of DFAIII with that of sodium caprate (C10), a well-known enhancer of TJ permeability, on the changes in TJ proteins, transport of paracellular markers, and effects of nine cellular signaling blockers using Caco-2 monolayers. The addition of DFAIII (0-100mmol/L) and C10 (0-10mmol/L) to the apical medium of the Caco-2 monolayers dose-dependently decreased transepithelial electrical resistance (TER), which is an indicator of TJ permeability. The reduction with C10 was much faster than that with DFAIII. Transport of the paracellular markers of various molecular weights (182-43,200) was elevated by the addition of 100mmol/L DFAIII and 10mmol/L C10. The transport rates were much in the presence of C10 than of DFAIII, while the reduction in TER by two treatments was similar (from 1000 to 300Omega cm(2)). Treatment with DFAIII and C10 changed the distribution of actin filament and claudin-1, but not occludin, junctional adhesion molecule-1, or zonula occludens-1; however, alterations in the patterns of the TJ proteins differed according to treatment. An inhibitor of myosin light chain kinase and a chelator of intracellular calcium ion ([Ca(2+)](i)) attenuated the TER reduction by C10, but not by DFAIII. These data demonstrate that the increase in TJ permeability induced by DFAIII results from the alterations to actin and claudin-1 via [Ca(2+)](i)-independent mechanisms.
Division of Applied Bioscience, Graduate School of Agriculture, Hokkaido University, Kita-9, Nishi-9, Kita-ku, Sapporo 060-8589, Japan.
Takuya
T
Suzuki
Hiroshi
H
Hara
D008841:Actin Cytoskeleton / Q000187:drug effects / Q000378:metabolism; D000935:Antifungal Agents / Q000494:pharmacology*; D001381:Azepines / Q000494:pharmacology; D001692:Biological Transport / Q000187:drug effects; D018938:Caco-2 Cells; D002614:Chelating Agents / Q000494:pharmacology; D062445:Claudin-1; D003652:Decanoic Acids / Q000494:pharmacology*; D004187:Disaccharides / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D017097:Electric Impedance; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D007413:Intestinal Mucosa / Q000187:drug effects* / Q000378:metabolism; D008565:Membrane Proteins / Q000187:drug effects / Q000378:metabolism; D009281:Naphthalenes / Q000494:pharmacology; D015398:Signal Transduction / Q000187:drug effects; D019108:Tight Junctions / Q000187:drug effects / Q000502:physiology
D000935:Antifungal Agents; D001381:Azepines; C568108:CLDN1 protein, human; D002614:Chelating Agents; D062445:Claudin-1; D003652:Decanoic Acids; D004187:Disaccharides; D004791:Enzyme Inhibitors; D008565:Membrane Proteins; D009281:Naphthalenes; C070571:ML 7; C031071:decanoic acid; C087758:difructose anhydride III